Osteosarcoma is an aggressive bone cancer that accounts for up to 85% of all malignant bone tumors in dogs. It most commonly strikes large and giant breeds between 7 and 10 years of age, and it carries a high risk of spreading to the lungs. If your dog has been diagnosed or you’re trying to understand what this disease looks like, here’s what you need to know.
Which Dogs Are Most at Risk
Osteosarcoma overwhelmingly affects large and giant breed dogs. In a study of 744 cases, Rottweilers were the most commonly diagnosed breed (17.1%), followed by Golden Retrievers (11.8%), Labrador Retrievers (10.9%), Doberman Pinschers (5.7%), Greyhounds (5.1%), and German Shepherds (4.7%). Saint Bernards, Irish Wolfhounds, Great Danes, and Great Pyrenees also appeared at elevated rates.
Most dogs are diagnosed between 7 and 10 years old, though the median age at diagnosis ranges from 6 to 9 years depending on the study. Smaller dogs can develop osteosarcoma too, but it’s far less common. The connection to body size isn’t fully understood, but the rapid bone growth these larger breeds experience during development is thought to play a role.
Where Tumors Develop
Osteosarcoma in dogs follows a recognizable pattern sometimes described by veterinarians as “away from the elbow, toward the knee.” The most common locations are the lower foreleg near the wrist (distal radius), the upper foreleg near the shoulder (proximal humerus), the lower thighbone near the knee (distal femur), and the upper shinbone (proximal tibia). These weight-bearing sites in the legs account for the vast majority of cases, though osteosarcoma can also occur in the skull, spine, ribs, or jaw.
How Osteosarcoma Destroys Bone
This cancer originates from bone-forming cells that begin replicating out of control. The tumor typically starts inside the central cavity of a bone, growing until it fills that space and then breaking through the outer cortex. As it grows, the cancer triggers both abnormal bone production and bone destruction. Cells that normally break down old bone become overactive around the tumor, dissolving healthy bone tissue and weakening the limb’s structural integrity. This combination of bone being eaten away and chaotic new bone being laid down is what creates the distinctive “sunburst” pattern visible on X-rays and causes the intense pain associated with the disease.
The weakening can become severe enough to cause a pathologic fracture, where the bone breaks during normal activity simply because the tumor has hollowed it out.
Signs and Symptoms
The earliest and most common sign is lameness or limping that doesn’t improve with rest. You might notice your dog favoring one leg, becoming reluctant to walk or play, or showing pain when a specific area of a limb is touched. Swelling at the tumor site often develops, and the area may feel firm or warm. Because the pain worsens as the tumor grows, many owners initially assume their dog has a sprain or arthritis, especially in older dogs.
In some cases, a pathologic fracture is the first indication that something more serious than joint pain is going on. If your dog suddenly becomes severely lame without an obvious injury, osteosarcoma is one of the conditions your vet will want to rule out.
How It’s Diagnosed
Diagnosis usually begins with X-rays of the affected limb. Osteosarcoma produces characteristic changes on radiographs: areas where bone has been destroyed mixed with regions of abnormal new bone growth, often with a disrupted outer bone surface. These images can be highly suggestive, but they aren’t enough on their own.
A bone biopsy is essential to definitively confirm osteosarcoma. This matters because other conditions, including fungal infections, can mimic the appearance of bone cancer on X-rays. The biopsy itself requires careful technique. The center of the tumor is often dead tissue due to poor blood supply, so veterinary pathologists need samples from the transition zones between normal and abnormal bone to get diagnostic tissue.
Once osteosarcoma is confirmed, chest X-rays or a CT scan of the lungs is the next step. This is critical because of how aggressively this cancer spreads.
The Metastasis Problem
This is the fact that shapes every treatment decision: approximately 90 to 95% of dogs with osteosarcoma are believed to already have microscopic spread to the lungs at the time of diagnosis. Only about 10% of dogs will have metastatic tumors large enough to show up on imaging at that point. The rest have cancer cells too small to detect but almost certainly present.
This is why surgery alone is not considered sufficient treatment. Removing the primary tumor addresses the pain and the visible disease, but without additional therapy targeting those invisible lung deposits, most dogs will develop detectable lung tumors within months.
Treatment: What to Expect
The standard approach combines surgery with chemotherapy. For tumors in the legs, amputation is the most common surgical option. Most dogs adapt remarkably well to three legs, often returning to near-normal activity within a few weeks. Limb-sparing surgery, which removes the tumor while preserving the leg, is available at some specialty centers but is only suitable for certain tumor locations.
Surgery alone carries a median survival time of only 3 to 4 months, primarily because of the microscopic lung spread that’s already underway. Adding chemotherapy after amputation extends the median survival to roughly 9 to 11 months. One-year survival rates with chemotherapy range from about 30% to 62% depending on the specific protocol used. Two-year survival rates fall to 7 to 28%.
A combination protocol using two different chemotherapy drugs given on the same day showed 47% of dogs alive at one year and 28% alive at two years. These numbers are sobering, but they represent real additional time with good quality of life for many dogs.
Palliative Care for Non-Surgical Candidates
For dogs that aren’t good candidates for surgery, whether due to tumor location, other health conditions, or owner preference, palliative radiation therapy is the primary tool for pain control. A typical protocol involves one treatment per week for four consecutive weeks. This doesn’t cure the cancer, but it can meaningfully reduce pain.
Bone-protective medications that slow down the destruction of healthy bone tissue can be combined with radiation. In one study, 75% of dogs treated with this combination showed noticeable pain improvement by day 30. This combination also reduced the risk of pathologic fractures: only 10% of dogs on the newer protocol fractured, compared to 44% on an older regimen.
Factors That Affect Prognosis
Several factors influence how a dog with osteosarcoma is likely to do. Dogs whose blood work shows elevated levels of a bone enzyme called alkaline phosphatase (ALP) tend to have shorter survival times, as higher levels correlate with more aggressive tumor activity. Dogs that already have visible lung metastasis at diagnosis have a significantly worse outlook than those whose imaging is still clear.
Tumor location matters too. Some limb sites respond better to treatment than others, and tumors in the axial skeleton (skull, spine, ribs) present different surgical challenges. Younger dogs with osteosarcoma sometimes face a more aggressive disease course than older dogs.
Immunotherapy on the Horizon
A cancer vaccine developed by researchers at Yale has been in clinical trials since 2016 and is currently under review by the USDA. The vaccine works by training the dog’s immune system to recognize and attack proteins that osteosarcoma cells overproduce on their surface. Unlike treatments that use a single manufactured antibody, this vaccine stimulates the dog’s own immune system to produce a broad range of antibodies that target multiple parts of those cancer proteins.
More than 300 dogs have been treated across 10 trial sites in the U.S. and Canada. According to the research team, the vaccine has increased 12-month survival rates from about 35% to 60% for dogs with certain cancers, including osteosarcoma. If approved, it would represent one of the most significant treatment advances for canine osteosarcoma in decades.